Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd3-hliNSmut and MVA-hliNSmut Prime-Boost for HCV
NCT03688061Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Dec 2017
- Primary completion
- Aug 2019
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAd3-hliNSmut and MVA-hliNSmut in hepatitis C (HCV) (3 arms), sponsored by University of Oxford. Primary endpoint: Proportion of volunteers who develop a grade 3 local and systemic reactions. Started Dec 2017; status: completed.
02
Drugs
ChAd3-hliNSmutMVA-hliNSmut
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03688061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03688061.